SCHEMBL6071124

SCHEMBL6071124

CCOC(=O)c1cccc2[nH]c3c(c12)CCc1c[nH]nc1-3

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 2/20 0.50
RIPK1 Q13546 2/20 0.50
AURKA O14965 1/20 0.50
KDM4E B2RXH2 2/20 0.40
CLEC4M Q9H2X3 1/20 0.39
TSHR P16473 1/20 0.39
CDK1 P06493 1/20 0.38
CDK2 P24941 1/20 0.38
CDC25B P30305 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 1/20 0.36
PARP1 P09874 1/20 0.36
MAPT P10636 2/20 0.35
JAK2 O60674 2/20 0.35
JAK3 P52333 2/20 0.35
GAA P10253 1/20 0.35
MAP3K5 Q99683 1/20 0.35
CCR6 P51684 1/20 0.35
MEN1 O00255 1/20 0.35
GABRP O00591 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6070436 0.88 NR4A2 (0.41) MAPK10RIPK1AURKAKDM4EJAK2
SCHEMBL6070636 0.84 PARP1 (0.42) MAPK10RIPK1AURKAPARP1
SCHEMBL6070790 0.79 MAPK10 (0.43) MAPK10RIPK1AURKAKDM4ETSHR
SCHEMBL6070444 0.77 MAPK10 (0.41) MAPK10RIPK1AURKAKDM4ETSHR
SCHEMBL6071266 0.77 KDM4E (0.62) MAPK10RIPK1AURKAKDM4ECDK1
SCHEMBL6071199 0.77 AURKA (0.53) MAPK10RIPK1AURKAKDM4ECDK1
SCHEMBL6071122 0.74 MAPK10 (0.41) MAPK10RIPK1AURKAKDM4ETSHR
SCHEMBL6071516 0.74 MAPK10 (0.59) MAPK10RIPK1AURKAKDM4ETSHR
SCHEMBL6070557 0.74 MAPK10 (0.41) MAPK10RIPK1AURKAKDM4ETSHR
SCHEMBL6009595 0.73 TSHR (0.61) KDM4ECLEC4MTSHRCDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 MAPK10 387/4885RIPK1 131/4885AURKA 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.